IQ-AI Ltd

  • News & Announcements
  • Shareholder Information
  • Investor Relations
  • Significant Shareholders
  • Publications
  • Home
  • Corporate News & Announcements
  • IQ-AI RNS News & Announcements
  • Start of Trading on the OTCQB Venture Market
 

News

Wednesday, 01 September 2021 / Published in IQ-AI RNS News & Announcements

Start of Trading on the OTCQB Venture Market

RNS Number : 3752K
IQ-AI Limited
01 September 2021
 

September 1, 2021

IQ-AI Limited

(“IQ-AI” or the “Company”)

 

IQ-AI shares to commence trading on the OTCQB Venture Market in the United States

 

IQ-AI Limited (LSE: IQAI) is pleased to announce that the Company’s ordinary shares will today begin trading on the OTCQB Venture Market (“OTCQB”) in the United States, under the ticker symbol “IQAIF”.

 

The Company’s objective in listing its shares on the OTCQB is to provide more efficient access to a new and materially larger pool of prospective US investors. The Directors believe that IQ-AI’s OTCQB listing will enable the Company to engage with a significant network of US investors, data distributors and media partners, ensuring that US investors have access to the same level of information and disclosure that is available to investors in the United Kingdom.

 

The OTCQB trading facility is provided through OTC Markets Group Inc, located in New York. OTC Markets Group Inc. operates the world’s largest electronic interdealer quotation system for US broker dealers and offers multiple media channels to increase the visibility of OTC-listed companies. Independent studies show that trading on the OTCQB by an international company offers a positive effect on the liquidity of its shares.

 

Trading on the OTCQB market will have no impact on the IQ-AI ordinary shares admitted to listing on the London Stock Exchange’s Main Market under the symbol “IQAI”, and no new ordinary shares have been admitted as part of the OTCQB listing. The Company will continue to rely on the announcements and disclosures it makes to the London Stock Exchange and has no Sarbanes-Oxley or SEC reporting requirements.

 

IQ-AI CEO, Trevor Brown, commented:

 

“The United States is home to some of the world’s most influential medical technology investors. By joining OTCQB, we now have an effective platform from which to reach a significantly larger investor audience and we look forward to providing investors in both the UK and the United States with regular progress updates at this exciting and pivotal time for the Company.”

 

Jonathan Dickson, VP of International Corporate Services at OTC Markets, said: 

 

“Congratulations to IQ-AI Ltd on joining the OTCQB Venture Market. We are pleased to support innovative and entrepreneurial international companies seeking to strengthen transparency and to provide better access to disclosure and trading for investors in the United States. Cross-trading on OTCQB in the U.S will enable IQ-AI, which is listed on the London Stock Exchange’s Main Market, to diversify its investor base and to expand its global engagement even further.”

 

The Company would like to thank Nikolaos Galanopoulos of Galanopoulos & Company, the corporate securities law firm that acted as Sponsor for the Company’s application to commence cross-trading on the OTCQB.

 

The Directors of the Company accept responsibility for the contents of this announcement.

 

IQ-AI Limited

Trevor Brown/Dr Qu Li/Vinod Kaushal

 

0207 469 0930

 

Peterhouse Capital Limited

Lucy Williams/Heena Karani

 

0207 220 9797

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
Article source

Recent Posts

  • Notice of AGM

    RNS Number : 4440K IQ-AI Limited 05 May 2022   ...
  • IB Broadens Quantitative Mapping

    RNS Number : 1476K IQ-AI Limited 03 May 2022   ...
  • IB Broadens Quantitative Mapping

    – Article source...
  • Final Results

    RNS Number : 7683J IQ-AI Limited 28 April 2022 ...
  • IQAI’s Sponsored Phase I Clinical Trial is Open

    RNS Number : 2319E IQ-AI Limited 09 March 2022 ...
Portions copyright © 2010-2022 IQ-AI Ltd. All Rights Reserved.
TOP
Our website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish.AcceptReject
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT